ONCOVIR CANADA INC
Clinical Study of Safety and Immunogenicity of Nasal Poly-ICLC (Hiltonol®) for Prophylaxis of COVID-19 in Healthy Adults — The overall goal of this project is to advance the clinical development of Poly-ICLC (Hiltonol®), a broad-spectrum antiviral drug candidate, as an innovative solution to strengthen medical preparedness against viral threats.